MicroRNA-22E Inhibits HER-3 Protein Expression to Facilitate Metastasis of Lung Adenocarcinomas
Hsin-Yuan Fang1, Tze-Yi Lin2, Shiow-Her Chiou3, Liang-Shun Wang4, Kuan-Chih Chow5*
1Departments of Surgery, School of Medicine, China Medical University, Taichung, Taiwan.
2Departments of Pathology, China Medical University Hospital, Taichung, Taiwan.
3Graduate Institute of Microbiology and Public Health, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.
4Graduate Institution of Clinical Medicine, Medical College, Taipei Medical University, Section of Thoracic Surgery, Departments of Surgery, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.
5Graduate Institute of Biomedical Sciences and Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.
DOI: 10.4236/jct.2015.64039   PDF   HTML   XML   2,871 Downloads   3,416 Views  


MicroRNA-22 (miR-22), a short non-coding RNA that post-transcriptionally regulates mRNA stability and protein synthesis, has been shown to enhance metastatic potential and to suppress HER-3, an important mRNA marker for non-small cell lung cancer (NSCLC). However, the effect of miR-22 has not been investigated in lung adenocarcinoma (LADC), the most common type of NSCLC in the Far East. In this study, we analyzed the role of miR-22 expression in LADC patients. Expression of miR-22 was detected by reverse-transcription polymerase chain reaction (RT-PCR), and confirmed by cDNA sequencing. Signals of miR-22 in LADC sections were identified using in situ hybridization (ISH). The association between miR-22 expression and survival was evaluated by the log-rank test. Induction of miR-22 expression and the effect on HER-3 levels, as well as the subsequent cell behavior were also investigated In vitro. Two types of miR-22: miR-22 and miR-22H, were detected by RT-PCR. The miR-22H had extra 13 bases, 5’-TGTGTTCAGTGGT-3’, at the 3’-end, and this segment was named miR-22E. Using ISH, miR-22E overexpression was detected in 225 (83.0%) of 271 LADC patients. A significant difference was found in cumulative survival between patients with high miR-22E levels and those with low miR-22E levels (p < 0.0001). In vitro, epidermal growth factor induced miR-22, but reduced HER-3 expression. Expression of miR-22 increased cell movement ability. In conclusion, expression of miR-22 is closely associated with tumor recurrence, metastasis and overall survival in LADC patients by suppressing HER-3 protein expression to enhance epithelial-mesenchymal transition and metastasis.

Share and Cite:

Fang, H. , Lin, T. , Chiou, S. , Wang, L. and Chow, K. (2015) MicroRNA-22E Inhibits HER-3 Protein Expression to Facilitate Metastasis of Lung Adenocarcinomas. Journal of Cancer Therapy, 6, 362-374. doi: 10.4236/jct.2015.64039.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Huang, S.-F., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H.-Y., et al. (2004) High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non-Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan. Clinical Cancer Research, 10, 8195-8203.
[2] Wu, J.-Y., Wu, S.-G., Yang, C.-H., Chang, Y.-L., Chang, Y.-C., Hsu, Y.-C., et al. (2011) Comparison of Gefitinib and Erlotinib in Advanced NSCLC and the Effect of EGFR Mutations. Lung Cancer, 72, 205-212.
[3] Chen, J.-T., Lin, T.-S., Chow, K.-C., Huang, H.-H., Chiou, S.-H., Chiang, S.-F., et al. (2006) Cigarette Smoking Induces Overexpression of Hepatocyte Growth Factor in Type II Pneumocytes and Lung Cancer cells. American Journal of Respiratory Cell and Molecular Biology, 34, 264-273.
[4] Chen, J.-T., Huang, C.-Y., Chiang, Y.-Y., Chen, W.-H., Chiou, S.-H., Chen, C.-Y., et al. (2008) HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells. American Journal of Respiratory Cell and Molecular Biology, 38,559-565.
[5] Hsu, N.Y., Ho, H.C., Chow, K.C., Lin, T.-Y., Shih, C.-S., Wang, L.-S., et al. (2001) Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker of Non-Small Cell Lung Cancer. Cancer Research, 61, 2727-2731.
[6] Chiang, Y.-Y., Chen, S.-L., Hsiao, Y.-T., Huang, C.-H., Lin, T.-Y., Chiang, I.-P., et al. (2009) Nuclear Expression of Dynamin-Related Protein 1 in Lung Adenocarcinomas. Modern Pathology, 22, 1139-1150.
[7] Fang, H.Y., Chang, C.L., Hsu, S.H., Huang, C.Y., Chiang, S.F., Chiou, S.H., et al. (2010) ATPase Family AAA Domain-Containing 3A Is a Novel Anti-Apoptotic Factor in Lung Adenocarcinoma Cells. Journal of Cell Science, 123, 1171-1180.
[8] You, W.-C., Chiou, S.-H., Huang, C.-Y., Chiang, S.-F., Yang, C.-L., Sudhakar, J.N., et al. (2013) Mitochondrial Protein ATPase Family, AAA Domain Containing 3A Correlates with Radioresistance in Glioblastoma. Neuro-Oncology, 15, 1342-1352.
[9] Chen, D.-R., Chu, C.-Y., Chen, C.-Y., Yang, H.-C., Chiang, Y.-Y., Lin, T.-Y., et al. (2008) Expression of Short Form Oncostatin M Receptor as a Decoy Receptor in Lung Adenocarcinomas. The Journal of Pathology, 215, 290-299.
[10] Chen, H.-Y., Yu, S.-L., Chen, C.-H., Chang, G.-C., Chen, C.-Y., Yuan, A., et al. (2007) A Five-Gene Signature and Clinical Outcome in Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 356, 11-20.
[11] Olayioye, M.A., Neve, R.M., Lane, H.A. and Hynes, N.E. (2000) The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer. The EMBO Journal, 19, 3159-3167.
[12] Sierke, S.L., Cheng, K., Kim, H.H. and Koland, J.G. (1997) Biochemical Characterization of the Protein Tyrosine kinase Homology Domain of the ErbB3 (HER3) Receptor Protein. Biochemical Journal, 322, 757-763.
[13] Steinberg, F., Zhuang, L., Beyeler, M., Kalin, R.E., Mullis, P.E., Brandli, A.W., et al. (2010) The FGFRL1 Receptor Is Shed from Cell Membranes, Binds Fibroblast Growth Factors (FGFs), and Antagonizes FGF Signaling in Xenopus Embryos. The Journal of Biological Chemistry, 285, 2193-2202.
[14] Bogdan, S. and Klambt, C. (2001) Epidermal Growth Factor Receptor Signaling. Current Biology, 11, R292-R295.
[15] Hellyer, N.J., Cheng, K. and Koland, J.G. (1998) ErbB3 (HER3) Interaction with the p85 Regulatory Subunit of Phosphoinositide 3-Kinase. Biochemical Journal, 333, 757-763.
[16] Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233.
[17] Patel, J.B., Appaiah, H.N., Burnett, R.M., Bhat-Nakshatri, P., Wang, G., Mehta, R., et al. (2011) Control of EVI-1 Oncogene Expression in Metastatic Breast Cancer Cells through microRNA miR-22. Oncogene, 30, 1290-1301.
[18] Larue, L. and Bellacosa, A. (2005) Epithelial-Mesenchymal Transition in Development and Cancer: Role of Phosphatidylinositol 3’Kinase/AKT Pathways. Oncogene, 24, 7443-7454.
[19] Bar, N. and Dikstein, R. (2010) miR-22 Forms a Regulatory Loop in PTEN/AKT Pathway and Modulates Signaling Kinetics. PLoS One, 5, e10859.
[20] Kasahara, K., Arao, T., Sakai, K., Matsumoto, K., Sakai, A., Kimura, H., et al. (2010) Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma. Clin Cancer Res, 16, 4616-4624.
[21] Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., et al. (2008) Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Research, 68, 9479-9487.
[22] Mountain, C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-1717.
[23] Kaplan, E.L. and Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481.
[24] Mantel, N. (1966) Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration. Cancer Chemotherapy Reports, 50, 163-170.
[25] Chen, C.-Y., Fang, H.-Y., Chiou, S.-H., Yi, S.-E., Huang, C.-Y., Chiang, S.-F., et al. (2011) Sumoylation of Eukaryotic Elongation Factor 2 Is Vital for Protein Stability and Anti-Apoptotic Activity in Lung Adenocarcinoma Cells. Cancer Science, 102, 1582-1589.
[26] Lee, Y., Jeon, K., Lee, J.T., Kim, S. and Kim, V.N. (2002) MicroRNA Maturation: Stepwise Processing and Subcellular Localization. The EMBO Journal, 21, 4663-4670.
[27] Flynt, A.S., Greimann, J.C., Chung, W.J., Lima, C.D. and Lai, E.C. (2010) MicroRNA Biogenesis via Splicing and Exosome-Mediated Trimming in Drosophila. Molecular Cell, 38, 900-907.
[28] Song, S.J., Poliseno, L., Song, M.S., Ala, U., Webster, K., Ng, C., et al. (2013) MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 154, 311-324.
[29] Kong, D.J., Li, Y.W., Wang, Z.W., Banerjee, S., Ahmad, A., Choi Kim, H.-R. and Sarkar, F.H. (2009) miR-200 Regulates PDGF-D-Mediated Epithelial-Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells. Stem Cells, 27, 1712-1721.
[30] Pecot, C.V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C.H., et al. (2013) Tumour Angiogenesis Regulation by the miR-200 Family. Nature Communications, 4, Article Number: 2427.
[31] Park, S.M., Gaur, A.B., Lengyel, E. and Peter, M.E. (2008) The miR-200 Family Determines the Epithelial Phenotype of Cancer Cells by Targeting the E-Cadherin Repressors ZEB1 and ZEB2. Genes & Development, 22, 894-907.
[32] Korpal, M., Ell, B.J., Buffa, F.M., Ibrahim, T., Blanco, M.A., Celià-Terrassa, T., et al. (2011) Direct Targeting of Sec23a by miR-200s Influences Cancer Cell Secretome and Promotes Metastatic Colonization. Nature Medicine, 17, 1101-1108.
[33] Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4, 988-1004.
[34] Shen, J., Xia, W.Y., Khotskaya, Y.B., Huo, L.F., Nakanishi, K., Lim, S.-O., et al. (2013) EGFR Modulates microRNA Maturation in Response to Hypoxia through Phosphorylation of AGO2. Nature, 497, 383-387.
[35] Jin, K., Mao, X.O., Sun, Y., Xie, L., Jin, L., Nishi, E., et al. (2002) Heparin-Binding Epidermal Growth Factor-Like Growth Factor: Hypoxia-Inducible Expression in Vitro and Stimulation of Neurogenesis in Vitro and in Vivo. The Journal of Neuroscience, 22, 5365-5373.
[36] Minakata, K., Takahashi, F., Nara, T., Hashimoto, M., Tajima, K., Murakami, A., et al. (2012) Hypoxia Induces Gefitinib Resistance in Non-Small-Cell Lung Cancer with Both Mutant and Wild-Type Epidermal Growth Factor Receptors. Cancer Science, 103, 1946-1954.
[37] Tavaluc, R.T., Hart, L.S., Dicker, D.T. and El-Deiry, W.S. (2007) Effects of Low Confluency, Serum Starvation and Hypoxia on the Side Population of Cancer Cell Lines. Cell Cycle, 6, 2554-2562.
[38] Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., et al. (2006) Unique MicroRNA Molecular Profiles in Lung Cancer Diagnosis and Prognosis. Cancer Cell, 9, 189-198.
[39] Chiang, Y.Y., Chow, K.C., Lin, T.Y., Chiang, I.P. and Fang, H.Y. (2014) Hepatocyte Growth Factor and HER2/Neu Downregulate Expression of Apoptosis-Inducing Factor in Non-Small Cell Lung Cancer. Oncology Reports, 31, 597-604.
[40] Lowery, A.J., Miller, N., Devaney, A., McNeill, R.E., Davoren, P.A., Lemetre, C., et al. (2009) MicroRNA Signatures Predict Oestrogen Receptor, Progesterone Receptor and HER2/Neureceptor Status in Breast Cancer. Breast Cancer Research, 11, R27.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.